Search Results - "Loveless, Sam"

Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes by Kodosaki, Eleftheria, Watkins, W John, Loveless, Sam, Kreft, Karim L, Richards, Aidan, Anderson, Valerie, Hurler, Lisa, Robertson, Neil P, Zelek, Wioleta M, Tallantyre, Emma C

“…Establishing biomarkers to predict multiple sclerosis diagnosis and prognosis has been challenging using a single biomarker approach. We hypothesised that a…”
Get full text

Complement activation in multiple sclerosis plaques: an immunohistochemical analysis by Ingram, Gillian, Loveless, Sam, Howell, Owain W, Hakobyan, Svetlana, Dancey, Bethan, Harris, Claire L, Robertson, Neil P, Neal, James W, Morgan, B Paul

“…Inflammation and complement activation are firmly implicated in the pathology of multiple sclerosis; however, the extent and nature of their involvement in…”
Get full text

CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis by Naughton, Michelle, Moffat, Jill, Eleftheriadis, George, de la Vega Gallardo, Nira, Young, Andrew, Falconer, John, Hawkins, Kristen, Pearson, Ben, Perbal, Bernard, Hogan, Andrew, Moynagh, Paul, Loveless, Sam, Robertson, Neil P, Gran, Bruno, Kee, Rachael, Hughes, Stella, McDonnell, Gavin, Howell, Owain, Fitzgerald, Denise C

“…Multiple sclerosis (MS) is an immune-mediated disease that damages myelin in the central nervous system (CNS). We investigated the profile of CCN3, a known…”
Get full text

Complement regulator factor H as a serum biomarker of multiple sclerosis disease state by Ingram, Gillian, Hakobyan, Svetlana, Hirst, Claire L., Harris, Claire L., Pickersgill, Trevor P., Cossburn, Mark D., Loveless, Sam, Robertson, Neil P., Morgan, Bryan Paul

“…Multiple sclerosis has a variable phenotypic presentation and subsequent disease course that, although unpredictable at disease onset, is of crucial importance…”
Get full text

053  Multiple Sclerosis Prevalence: Cardiff and Vale population-based cohort by Hawken, Jonathan, Robertson, Neil, Tallantyre, Emma, Wynford-Thomas, Ray, Anderson, Valerie, Loveless, Sam

“…As treatment options expand for all disease phases of MS, accurate epidemiological data reflecting contemporary patterns of disease by direct clinical…”
Get full text

T-cell response and COVID-19 infection following COVID-19 booster vaccinations in pwMS treated with ocrelizumab by Zaloum, Safiya A, Upcott Matthew, Vickaryous Nicola, Scurr, Martin J, Anderson, Valerie, Loveless, Sam, Rios, Francesca, Katila, George, Tallantyre, Emma C, Dobson, Ruth

“…IntroductionPeople with multiple sclerosis (pwMS) treated with ocrelizumab mount a T-cell response to vaccination, irrespective of humoral response. Correlates…”
Get full text

158 CSF T-cell counts in multiple sclerosis diagnosis and prognosis by Hrastelj, James, Willis, Mark, Bishop, Mark, Loveless, Sam, Tallantyre, Emma, Robertson, Neil

“…BackgroundIdentifying diagnostic and prognostic biomarkers in multiple sclerosis (MS) remains challenging. Cerebrospinal fluid (CSF) is a potentially valuable…”
Get full text

058  Serum neurofilament-light concentration and real-world outcome in MS by Anderson, Valerie, Bentley, Emily, Loveless, Sam, Bianchi, Lucia, Harding, Katharine E, Thomas, Ray Wynford, Giovannoni, Gavin, Robertson, Neil P, Marta, Monica, Tallantyre, Emma C

“…Predicting clinical outcome in multiple sclerosis (MS) remains challenging, and biomarkers capable of providing prognostic information would be valuable in…”
Get full text

Relevance of Multiple Sclerosis Severity Genotype in Predicting Disease Course: A Real‐World Cohort by Kreft, Karim L., Uzochukwu, Emeka, Loveless, Sam, Willis, Mark, Wynford‐Thomas, Ray, Harding, Katharine E., Holmans, Peter, Lawton, Michael, Tallantyre, Emma C., Robertson, Neil P.

“…Objective Currently, 233 genetic loci are known to be associated with susceptibility to multiple sclerosis (MS). Two independent pivotal severity genome‐wide…”
Get full text

Fault architecture and deformation processes within poorly lithified rift sediments, Central Greece by Loveless, Sian, Bense, Victor, Turner, Jenni

“…Deformation mechanisms and resultant fault architecture are primary controls on the permeability of faults in poorly lithified sediments. We characterise fault…”
Get full text

Complement is activated in progressive multiple sclerosis cortical grey matter lesions by Watkins, Lewis M, Neal, James W, Loveless, Sam, Michailidou, Iliana, Ramaglia, Valeria, Rees, Mark I, Reynolds, Richard, Robertson, Neil P, Morgan, B Paul, Howell, Owain W

“…The symptoms of multiple sclerosis (MS) are caused by damage to myelin and nerve cells in the brain and spinal cord. Inflammation is tightly linked with…”
Get full text

Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis by Loveless, Sam, Neal, James W., Howell, Owain W., Harding, Katharine E., Sarkies, Patrick, Evans, Rhian, Bevan, Ryan J., Hakobyan, Svetlana, Harris, Claire L., Robertson, Neil P., Morgan, Bryan Paul

“…The complement pathway has potential contributions to both white (WM) and grey matter (GM) pathology in Multiple Sclerosis (MS). A quantitative assessment of…”
Get full text

Serum neurofilament-light concentration and real-world outcome in MS by Anderson, Valerie, Bentley, Emily, Loveless, Sam, Bianchi, Lucia, Harding, Katharine E., Wynford-Thomas, Ray A., Joseph, Fady, Giovannoni, Gavin, Gnanapavan, Sharmilee, Robertson, Neil P., Marta, Monica, Tallantyre, Emma C.

“…Prognostication in multiple sclerosis (MS) remains challenging. Biomarkers capable of providing this information at diagnosis would be valuable in shaping…”
Get full text

High levels of soluble CD59 in CSF compared to plasma suggests intrathecal source of soluble CD59 by Zelek, Wioleta, Willems, Loek, Brandwijk, Ricardo, Loveless, Sam, Robertson, Neil R., Morgan, B. Paul

Get full text

COMPLEMENT ACTIVATION IN MULTIPLE SCLEROSIS AND NMO SPECTRUM DISORDERS by Luppe, Sebastian, Hakobyan, Svetlana, Evans, David, Harding, Katherine, Loveless, Sam, Robertson, Neil, Morgan, B. Paul

“…MS and NMOSD are inflammatory CNS diseases and early manifestations can be similar creating management problems, since MS drugs may be ineffective and/or…”
Get full text

Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration by Gelissen, Liza M.Y., Loveless, Sam, Toorop, Alyssa A., Howlett, Jayne, Loeff, Floris C., Rispens, Theo, Killestein, Joep, Tallantyre, Emma C., van Kempen, Zoé L.E.

“…Several studies reported lower drug concentrations with subcutaneous natalizumab compared to intravenous natalizumab. With the emergence of extended interval…”
Get full text

Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59 by Zelek, Wioleta M, Watkins, Lewis M, Howell, Owain W, Evans, Rhian, Loveless, Sam, Robertson, Neil P, Beenes, Marijke, Willems, Loek, Brandwijk, Ricardo, Morgan, B Paul

“…Background: CD59, a broadly expressed glycosylphosphatidylinositol-anchored protein, is the principal cell inhibitor of complement membrane attack on cells. In…”
Get full text

Using biomarkers to predict clinical outcomes in multiple sclerosis by Castle, Daniel, Wynford-Thomas, Ray, Loveless, Sam, Bentley, Emily, Howell, Owain W, Tallantyre, Emma C

“…Long-term outcomes in multiple sclerosis (MS) are highly varied and treatment with disease-modifying therapies carries significant risks. Finding tissue…”
Get more information

Complement system biomarkers in demyelinating disease by Zelek, Wioleta, Fathalla, Dina, Orme, Rowan P, Morgan, Angharad, Touchard, Samuel, O’Hagan, Caroline, Loveless, Sam, Robertson, Neil, Morgan, B. Paul

Get full text